Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease

Proteomics - Clinical Applications

Volumn 6, Issue 3-4, 2012, Pages 201-211

  Donovan, Laura E ^a   Higginbotham, Lenora ^a   Dammer, Eric B ^a   Gearing, Marla ^a   Rees, Howard D ^a   Xia, Qiangwei ^a   Duong, Duc M ^a   Seyfried, Nicholas T ^a   Lah, James J ^a   Levey, Allan I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Membrane enrichment; Neurodegeneration

Indexed keywords

ALPHA 2 MACROGLOBULIN; ASPARTATE AMINOTRANSFERASE; BINDING PROTEIN; CORE PROTEIN; CREATINE KINASE; CREATINE KINASE B TYPE; HEAT SHOCK COGNATE 71 PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 BETA; PLECTIN; PLECTIN 1; PROTEASOME; PROTEASOME SUBUNIT ALPHA TYPE 1; PROTEOME; PYRUVATE KINASE; PYRUVATE KINASE ISOZYME M1; PYRUVATE KINASE ISOZYME M2; SYNTAXIN BINDING PROTEIN 1; TAU PROTEIN; TENASCIN; UBIQUITIN CARBOXY TERMINAL HYDROLASE ISOZYME L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; VERSICAN CORE PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BIOCHEMISTRY; BRAIN TISSUE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MALE; NEUROPATHOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PROTEOMICS; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

AGED; ALZHEIMER DISEASE; AUTOPSY; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CELL MEMBRANE; CHROMATOGRAPHY, LIQUID; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; MUNC18 PROTEINS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TAU PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84860344567     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100068     Document Type: Article

References (57)

1. Prince, M., Jackson, J. (Eds.), World Alzheimer's Report. Alzheimer's Dis. Int. 2009, 1-92.
2. Goedert, M., Spillantini, M. G., A century of Alzheimer's disease. Science 2006, 314, 777-781.
3. Alzheimer's Association, 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011, 7, 208-244.
4. Daviglus, M. L., Bell, C. C., Berrettini, W., Bowen, P. E. et al., National Institutes of Health state-of-the-science conference statement: preventing Alzheimer disease and cognitive decline. Ann. Intern. Med. 2010, 153, 176-181.
5. Blennow, K., de Leon, M. J., Zetterberg, H., Alzheimer's disease. Lancet 2006, 368, 387-403.
6. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G. et al., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82, 4245-4249.
7. Lee, V., Balin, B., Otvos, L., Trojanowski, J., A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991, 251, 675-678.
8. Glenner, G. G., Wong, C. W., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Bioph. Res. Co. 1984, 120, 885-890.
9. Hardy, J. A., Higgins, G. A., Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256, 184-185.
10. Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J. et al, Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J. Neurosci. 2010, 30, 14946-14954.
11. Herskowitz, J. H., Seyfried, N. T., Gearing, M., Kahn, R. A. et al., Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-β production. J. Biol. Chem. 2011, 286, 6117-6127.
12. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
13. Bantscheff, M., Schirle, M., Sweetman, G., Rick, J. et al., Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem. 2007, 389, 1017-1031.
14. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
15. Geiger, T., Cox, J., Ostasiewicz, P., Wisniewski, J. R. et al., Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods, 7, 383-385.
16. Ishihama, Y., Sato, T., Tabata, T., Miyamoto, N. et al., Quantitative mouse brain proteomics using culture-derived isotope tags as internal standards. Nat. Biotech. 2005, 23, 617-621.
17. Old, W. M., Meyer-Arendt, K., Aveline-Wolf, L., Pierce, K. G. et al., Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol. Cell. Proteomics 2005, 4, 1487-1502.
18. Matt, P., Fu, Z., Fu, Q., Van Eyk, J. E., Biomarker discovery: proteome fractionation and separation in biological samples. Physiol. Genomics 2008, 33, 12-17.
19. Braak, H., Braak, E., Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239-259.
20. Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M. et al., The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41, 479-486.
21. Seyfried, N. T., Huysentruyt, L. C., Atwood, J. A., 3rd, Xia, Q. et al., Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: a membrane proteomics approach. Cancer Lett. 2008, 263, 243-252.
22. Xu, P., Duong, D. M., Peng, J., Systematical optimization of reverse-phase chromatography for shotgun proteomics. J. Proteome Res. 2009, 8, 3944-3950.
23. Gozal, Y. M., Duong, D. M., Gearing, M., Cheng, D. et al., Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease. J. Proteome Res. 2009, 8, 5069-5079.
24. Peng, J., Elias, J. E., Thoreen, C. C., Licklider, L. J. et al., Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2003, 2, 43-50.
25. Seyfried, N. T., Xu, P., Duong, D. M., Cheng, D. et al., Systematic approach for validating the ubiquitinated proteome. Anal. Chem. 2008, 80, 4161-4169.
26. Herskowitz, J. H., Seyfried, N. T., Duong, D. M., Xia, Q. et al., Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. J. Proteome Res. 2010, 9, 6368-6379.
27. Kislinger, T., Cox, B., Kannan, A., Chung, C. et al., Global survey of organ and organelle protein expression in mouse: combined proteomic and transcriptomic profiling. Cell 2006, 125, 173-186.
28. Xia, Q., Cheng, D., Duong, D. M., Gearing, M. et al., Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry. J. Proteome Res. 2008, 7, 2845-2851.
29. Xia, Q., Liao, L., Cheng, D., Duong, D. M. et al., Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008, 13, 3850-3856.
30. Whittiker, V. P., Handbook of Neurochemistry, Plenum Press, New York, 1969, pp. 327-364.
31. Kim, S. I., Voshol, H., van Oostrum, J., Hastings, T. G. et al., Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Neurochem. Res. 2004, 29, 1317-1331.
32. Krogh, A., Larsson, B., von Heijne, G., Sonnhammer, E. L. L., Predicting transmembrane protein topology with a hidden markov model: application to complete genomes. J. Mol. Biol. 2001, 305, 567-580.
33. Xia, Q., Hendrickson, E. L., Zhang, Y., Wang, T. et al., Quantitative proteomics of the Archaeon Methanococcus maripaludis validated by microarray analysis and real time PCR. Mol. Cell. Proteomics 2006, 5, 868-881.
34. Xia, Q., Wang, T., Park, Y., Lamont, R. J. et al., Differential quantitative proteomics of Porphyromonas gingivalis by linear ion trap mass spectrometry: non-label methods comparison, q-values and LOWESS curve fitting. Int. J. Mass Spectrom. 2007, 259, 105-116.
35. Xia, Q., Wang, T., Taub, F., Park, Y. et al., Quantitative proteomics of intracellular Porphyromonas gingivalis. Proteomics 2007, 7, 4323-4337.
36. Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D. et al., Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004, 279, 13256-13264.
37. Jacobs, E. H., Williams, R. J., Francis, P. T., Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11α protein up-regulation in Alzheimer's disease. Neuroscience 2006, 138, 511-522.
38. Blacker, D., Wilcox, M. A., Laird, N. M., Rodes, L. et al., Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 1998, 19, 357-360.
39. Lewis, S. B., Wolper, R., Chi, Y.-Y., Miralia, L. et al., Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage. J. Neurosc. Res. 2010, 88, 1475-1484.
40. Tadokoro, S., Kurimoto, T., Nakanishi, M., Hirashima, N., Munc18-2 regulates exocytotic membrane fusion positively interacting with syntaxin-3 in RBL-2H3 cells. Mol. Immunol. 2007, 44, 3427-3433.
41. Smyth, A. M., Rickman, C., Duncan, R. R., Vesicle fusion probability is determined by the specific interactions of Munc18. J. Biol. Chem. 2010, 285, 38141-38148.
42. Baker, D. L., Seyfried, N. T., Li, H., Orlando, R. et al., Determination of protein-RNA interaction sites in the Cbf5-H/ACA guide RNA complex by mass spectrometric protein footprinting. Biochemistry 2008, 47, 1500-1510.
43. Brandt, R., Léger, J., Lee, G., Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J. Cell. Biol. 1995, 131, 1327-1340.
44. Maas, T., Eidenmüller, J., Brandt, R., Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J. Biol. Chem. 2000, 275, 15733-15740.
45. Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M. et al., Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models. Cell 2010, 142, 387-397.
46. Day, I. N. M., Thompson, R. J., UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog. Neurobiol. 2010, 90, 327-362.
47. Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z. et al., The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111, 209-218.
48. Hsu, S. H., Lai, M. C., Er, T. K., Yang, S. N. et al., Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts. Clin. Chim. Acta 2010, 411, 1920-1928.
49. Liu, Z., Meray, R. K., Grammatopoulos, T. N., Fredenburg, R. A. et al., Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc. Natl. Acad. Sci. USA 2009, 106, 4635-4640.
50. Zetterberg, M., Sjolander, A., von Otter, M., Palmer, M. et al., Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease. Mol. Neurodegeneration 2010, 5, 11.
51. Ho, A., Morishita, W., Hammer, R. E., Malenka, R. C. et al., A role for Mints in transmitter release: Mint 1 knockout mice exhibit impaired GABAergic synaptic transmission. Proc. Natl. Acad. Sci. 2003, 100, 1409-1414.
52. Narita, M., Holtzman, D. M., Schwartz, A. L., Bu, G., α2-macroglobulin complexes with and mediates the endocytosis of β-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 1997, 69, 1904-1911.
53. Liao, A., Nitsch, R. M., Greenberg, S. M., Finckh, U. et al., Genetic association of an (α2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum. Mol. Genet. 1998, 7, 1953-1956.
54. Saunders, A. J., Bertram, L., Mullin, K., Sampson, A. J. et al., Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum. Mol. Genet. 2003, 12, 2765-2776.
55. Schlattner, U., Tokarska-Schlattner, M., Wallimann, T., Mitochondrial creatine kinase in human health and disease. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2006, 1762, 164-180.
56. Lynn, B. C., Wang, J., Markesbery, W. R., Lovell, M. A., Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. J. Alz. Dis. 2010, 19, 325-339.
57. Peng, J., Gygi, S. P., Proteomics: the move to mixtures. J. Mass Spectrom. 2001, 36, 1083-1091.